Ropes Wealth Advisors LLC lifted its stake in shares of Stryker Co. (NYSE:SYK) by 41.6% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 708 shares of the medical technology company’s stock after acquiring an additional 208 shares during the quarter. Ropes Wealth Advisors LLC’s holdings in Stryker were worth $140,000 at the end of the most recent reporting period.
Other large investors also recently made changes to their positions in the company. ERTS Wealth Advisors LLC bought a new position in shares of Stryker during the 4th quarter valued at approximately $25,000. Northwest Wealth Management LLC raised its holdings in Stryker by 103.6% during the 4th quarter. Northwest Wealth Management LLC now owns 169 shares of the medical technology company’s stock valued at $26,000 after buying an additional 86 shares during the period. Semmax Financial Advisors Inc. purchased a new stake in Stryker during the 4th quarter valued at $28,000. Horan Securities Inc. purchased a new stake in Stryker during the 4th quarter valued at $30,000. Finally, Truehand Inc purchased a new stake in Stryker during the 4th quarter valued at $30,000. Institutional investors own 74.61% of the company’s stock.
In other news, VP Yin C. Becker sold 15,240 shares of the stock in a transaction on Thursday, March 21st. The stock was sold at an average price of $198.03, for a total transaction of $3,017,977.20. Following the transaction, the vice president now owns 16,577 shares of the company’s stock, valued at approximately $3,282,743.31. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, VP Michael Damon Hutchinson sold 3,936 shares of the stock in a transaction on Monday, March 25th. The stock was sold at an average price of $194.10, for a total value of $763,977.60. Following the transaction, the vice president now directly owns 12,841 shares in the company, valued at approximately $2,492,438.10. The disclosure for this sale can be found here. Insiders have sold a total of 131,071 shares of company stock worth $24,689,161 in the last three months. Corporate insiders own 7.20% of the company’s stock.
SYK stock opened at $193.42 on Tuesday. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.41 and a current ratio of 2.02. Stryker Co. has a twelve month low of $144.75 and a twelve month high of $199.85. The firm has a market capitalization of $71.89 billion, a price-to-earnings ratio of 26.46, a price-to-earnings-growth ratio of 2.37 and a beta of 0.88.
Stryker (NYSE:SYK) last released its earnings results on Tuesday, January 29th. The medical technology company reported $2.18 earnings per share for the quarter, topping analysts’ consensus estimates of $2.15 by $0.03. Stryker had a return on equity of 27.60% and a net margin of 26.12%. The business had revenue of $3.80 billion for the quarter, compared to analyst estimates of $3.73 billion. Sell-side analysts predict that Stryker Co. will post 8.13 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th will be given a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a dividend yield of 1.08%. The ex-dividend date of this dividend is Thursday, March 28th. Stryker’s payout ratio is 28.45%.
Several analysts recently weighed in on SYK shares. BTIG Research increased their price target on Stryker to $211.00 and gave the company a “buy” rating in a report on Monday, March 18th. Evercore ISI upgraded Stryker from an “in-line” rating to an “outperform” rating and set a $156.75 price target on the stock in a report on Wednesday, January 2nd. Piper Jaffray Companies restated an “overweight” rating and set a $205.00 price target on shares of Stryker in a report on Friday, March 1st. Morgan Stanley decreased their price target on Stryker from $212.00 to $197.00 and set an “overweight” rating on the stock in a report on Wednesday, January 2nd. Finally, SunTrust Banks increased their price target on Stryker to $205.00 and gave the company a “positive” rating in a report on Monday, February 4th. Eight analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $192.13.
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.
Further Reading: SEC Filing
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK).
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.